Literature DB >> 1691611

Serum alpha-fetoprotein and its lectin reactivity in liver diseases: a review.

J T Wu1.   

Abstract

Increased serum concentration of alpha-fetoprotein (AFP) can be found in benign and malignant liver diseases, in yolk sac tumors, and in several nonhepatic neoplasms at advanced stage. The frequency and level of elevated serum AFP are highest in hepatocellular carcinoma (HCC) and yolk sac tumors. Most levels of serum AFP in HCC are greater than 500 ng per mL, whereas the serum AFP in most of the benign liver diseases is only moderately elevated and is transient in nature. Determination of lectin reactivity of serum AFP is helpful for the differentiation of HCC from other diseases associated with elevated serum AFP. Determination of Len culinaris agglutinin (LCA) reactivity of serum AFP is useful for the differentiation of HCC from benign liver diseases, and for early detection of hepatoma. Determination of concanavalin A (Con A) nonreactive AFP variant is useful for the differentiation of HCC from yolk sac tumors and may also allow for the differentiation of HCC from nonhepatic neoplasms. However, reaction with several lectins may be required if differentiation among various nonhepatic neoplasms is needed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691611

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  20 in total

1.  Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases.

Authors:  T L Wu; C P Chang; K C Tsao; C F Sun; J T Wu
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy.

Authors:  J T Wu; T L Wu; C P Chang; K C Tsao; C F Sun
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 3.  The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities.

Authors:  Huiyuan Tang; Peter Hsueh; Doron Kletter; Marshall Bern; Brian Haab
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

4.  Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry.

Authors:  Ryo Yamashita; Yuko Fujiwara; Kohei Ikari; Keiko Hamada; Asuka Otomo; Kazuki Yasuda; Mitsuhiko Noda; Yasushi Kaburagi
Journal:  Mol Cell Biochem       Date:  2006-11-16       Impact factor: 3.396

5.  Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.

Authors:  Hasan Ozkan; Harun Erdal; Erdem Koçak; Hüseyin Tutkak; Zihni Karaeren; Mustafa Yakut; Seyfettin Köklü
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

6.  Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from nonmucinous pancreatic cysts.

Authors:  Zheng Cao; Kevin Maupin; Bryan Curnutte; Brian Fallon; Christa L Feasley; Elizabeth Brouhard; Richard Kwon; Christopher M West; John Cunningham; Randall Brand; Paola Castelli; Stefano Crippa; Ziding Feng; Peter Allen; Diane M Simeone; Brian B Haab
Journal:  Mol Cell Proteomics       Date:  2013-07-08       Impact factor: 5.911

Review 7.  Alpha-fetoprotein-producing esophageal adenocarcinoma: a mimicker of hepatocellular carcinoma.

Authors:  Jeremy Wang; Wendy Liu; Keyur Parikh; Anthony Benjamin Post
Journal:  Clin J Gastroenterol       Date:  2016-12-19

8.  Characterizing Protein Glycosylation through On-Chip Glycan Modification and Probing.

Authors:  Bryan S Reatini; Elliot Ensink; Brian Liau; Jessica Y Sinha; Thomas W Powers; Katie Partyka; Marshall Bern; Randall E Brand; Pauline M Rudd; Doron Kletter; Richard Drake; Brian B Haab
Journal:  Anal Chem       Date:  2016-11-15       Impact factor: 6.986

Review 9.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

10.  Current management of hepatocellular carcinoma.

Authors:  Ana Maria Crissien; Catherine Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.